Improved glycemic control without weight gain using triple therapy in type 2 diabetes

Area of Science:

• Endocrinology
• Metabolic Diseases
• Pharmacology

Background:

• Type 2 diabetes management often requires combination therapy to achieve glycemic control.
• Insulin, metformin, and thiazolidinediones are common agents used in diabetes treatment.
• Evaluating sequential and triple therapy regimens is crucial for optimizing patient outcomes.

Purpose of the Study:

• To assess the safety and efficacy of adding a thiazolidinedione (troglitazone) to existing insulin and metformin dual therapy.
• To compare the outcomes of triple therapy versus dual therapy in type 2 diabetes patients.
• To determine the impact on HbA1c levels, insulin dosage, and weight changes.

Main Methods:

• A 4-month dual therapy phase with insulin and metformin or insulin and troglitazone.
• An subsequent 4-month triple therapy phase adding metformin or troglitazone.
• Monitoring of HbA1c levels, total daily insulin dose, and body weight.

Main Results:

• Triple therapy significantly reduced HbA1c levels compared to dual therapy in both groups.
• Significant reductions in total daily insulin dose were observed with triple therapy, particularly when troglitazone was added.
• Weight gain was observed with insulin and troglitazone but was avoided when metformin preceded troglitazone addition.

Conclusions:

• Triple therapy with insulin, metformin, and troglitazone is safe and effective for type 2 diabetes.
• This regimen leads to improved glycemic control and reduced insulin requirements.
• Strategic sequencing of metformin and thiazolidinedione addition can prevent weight gain.